Kaitlyn Bader, Senior Editor

Learn more about the in-depth topics covered in the August 2023 issue of Dermatology Times.

From its clinical study, 97% of patients saw improvement in acne scars after 3 treatment sessions.

The post hoc analysis published in JAMA Dermatology studied the safety and efficacy of tralokinumab in adults aged 65 and older.

ICYMI, this week we had stories about clascoterone cream 1% for acne vulgaris management, CRH-R1 increases in psoriasis and actinic keratosis mast cells, cannabinoid use in dermatology, and more.

Providers have been eagerly awaiting the approval of VP-102, as molluscum contagiosum accounts for approximately 1% of all diagnosed skin conditions.

Alexandra Golant, MD, and Mona Shahriari, MD, shared pearls regarding the role of nonsteroidal topicals in the treatment of plaque psoriasis.

This week’s collection of the latest dermatologic studies covers PPT5α for androgenetic alopecia, fractional ablative CO2 laser and concurrent isotretinoin treatment for acne scars, vitamin D insufficiency and 25-hydroxy vitamin D levels related to cutaneous melanoma, and a literature review of baricitinib for alopecia areata.

Verrica’s statement follows the FDA’s warning from June 1, 2023.

Collaboration between dermatologists and gynecologists can improve patient quality of life and outcomes in vSCC treatment.

Timber Pharmaceuticals has been developing TMB-001 for the treatment of congenital ichthyosis.

ICYMI, this week we had stories about counting down to Fall Clinical in Vegas, clascoterone cream 1% for acne vulgaris management, VP-315 for basal cell carcinoma lesions, and more.

This week’s collection of the latest dermatologic studies covers distinguishing between granular cell tumors and melanoma, methotrexate and biologics for anxiety and depression among PsO patients, botulinum toxin for scalp conditions, and a review of the SPRING study for guselkumab.

Dermatology Times is counting down to the annual Fall Clinical conference in Las Vegas, Nevada, with our top 5 headlines and highlights from this year's PA and NP summer conference.

ICYMI, this week we had stories about rising derm stars from the World Congress of Dermatology, secukinumab for pediatric patients with plaque psoriasis, remibrutinib for rapid symptom control of urticaria, and more.

This week’s collection of the latest dermatologic studies covers an evaluation of the human stratum corneum with confocal Raman micro-spectroscopy, anti-mBP180 antibodies from mice, an updated review of alopecia areata comorbidities, and an ecchymotic patch related to chronic lymphocytic leukemia.

This week’s collection of the latest dermatologic studies covers defining biomarkers to predict treatment outcome based on immune checkpoint inhibitors, erythrodermic psoriasis in pediatric patients, surgical treatment of vulvar squamous cell carcinoma, and new and existing therapies for hand eczema.

Both companies are hoping to make a positive impact in the neoadjuvant setting of cutaneous squamous cell carcinoma.

Learn more about the in-depth topics covered in the July 2023 issue of Dermatology Times®.

ICYMI, this week we had stories about the psychological effects of cosmetic procedures, upadacitinib phase 3 trial for hidradenitis suppurativa, decreased levels of vitamin D associated with psoriasis severity, and more.

Each month, Dermatology Times® features a roundup of products trending in consumer skin care. Find out what products are popular for the month of July.

V940-001 is the first phase 3 study of a planned comprehensive clinical development program initiated after the positive primary analysis of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial.

This week’s collection of the latest dermatologic studies covers benzoyl peroxide gel with oral doxycycline compared to lymecycline, interactions between the aesthetic device industry and dermatologists, nasal soft tissue pliability, and Merkel cell carcinoma in situ with reticulated infundibulocystic proliferation.

Both therapies for alopecia areata and completely resected stage IIB/C melanoma could be approved by the EC for patients aged 12 years or older.

ICYMI, this week we had stories about managing Merkel cell carcinoma in patients with skin of color, addressing disparities in atopic dermatitis with telehealth, ruxolitinib for rapid pruritus reduction, and more.

Verrica’s VP-102 is the first FDA-approved treatment for molluscum lesions.

Introducing our newest weekly series, the Journal Digest, a collection of trending studies from leading dermatology journals. This week’s first edition covers IVIg treatment for autoimmune bullous dermatoses, body-focused repetitive behaviors, hormonal treatments for HS, dupilumab and skin barrier function, and a 2023 alopecia areata update.

The goal of a January 5, 2024, PDUFA date for berdazimer gel, 10.3%, continues with pre-approval inspection already complete.

AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component.

Coverage for eligible patients began July 12, 2023.

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.